跳至內容

莫米松

維基百科,自由的百科全書
莫米松
臨床資料
商品名英語Drug nomenclatureNasonex, Asmanex, Elocon, othersMometasone Use During Pregnancy. Drugs.com. 14 February 2020 [1 April 2020]. (原始內容存檔於2020-10-26). </ref>
其他名稱LAS-41002, 9α,21-Dichloro-11β,17α-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione 17α-(2-furoate)
給藥途徑Topical, inhalation (nasal spray)
藥物類別英語Drug classCorticosteroid; Glucocorticoid
ATC碼
法律規範狀態
法律規範
藥物動力學數據
生物利用度Nasal spray is virtually undetectable in plasma; but systemic availability is comparable to fluticasone[3]
血漿蛋白結合率98% to 99%
藥物代謝Liver
生物半衰期5.8 hours
識別資訊
  • (9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate
CAS號105102-22-5
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
ECHA InfoCard100.125.600 編輯維基數據鏈接
化學資訊
化學式C22H28Cl2O4 for mometasone
C27H30O6Cl2 as furoate
3D模型(JSmol英語JSmol
  • CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)O)C)O)Cl)C

  • CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)OC(=O)C5=CC=CO5)C)O)Cl)C
  • InChI=1S/C22H28Cl2O4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1 checkY
  • Key:QLIIKPVHVRXHRI-CXSFZGCWSA-N checkY

  • InChI=1S/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3/t15-,18+,19+,21+,24+,25+,26+,27+/m1/s1
  • Key:WOFMFGQZHJDGCX-ZULDAHANSA-N

莫米松Mometasone),是一種糖皮質激素,用於治療某些皮膚病花粉熱哮喘[4] [5] [6],具體用於預防哮喘發作(非治療)。[4]可應用於皮膚、吸入或鼻部。[4][5][6][7]

莫米松用於哮喘的常見副作用包括鵝口瘡[4],因此建議使用後漱口,[4]長期使用可能會增加患青光眼白內障的風險。[4]應用於鼻部的常見副作用包括上呼吸道感染流鼻血[6]應用於皮膚時的常見副作用包括痤瘡、皮膚萎縮和瘙癢。[5]它通過減少炎症起作用。[4]

糠酸莫米松於1981年獲得專利,並於1987年開始醫用。[8]它在世界衛生組織的基本藥物清單上[9],可作為通用藥物使用。 [10]2017年,它是美國第197種最常用的處方藥,共開出超過200萬張處方。[11] [12]

參考資料

  1. ^ Nasonex- mometasone furoate spray, metered. DailyMed. 26 January 2011 [19 June 2022]. (原始內容存檔於2022-11-05). 
  2. ^ https://www.ema.europa.eu/documents/psusa/mometasone-list-nationally-authorised-medicinal-products-psusa/00002085/202005_en.pdf [裸網址]
  3. ^ Tayab ZR, Fardon TC, Lee DK, Haggart K, McFarlane LC, Lipworth BJ, Hochhaus G. Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate. British Journal of Clinical Pharmacology. November 2007, 64 (5): 698–705. PMC 2203259可免費查閱. PMID 17509041. doi:10.1111/j.1365-2125.2007.02919.x. 
  4. ^ 4.0 4.1 4.2 4.3 4.4 4.5 4.6 Mometasone Furoate Monograph for Professionals. Drugs.com. American Society of Health-System Pharmacists. [11 March 2019]. (原始內容存檔於2016-10-07) (英語). 
  5. ^ 5.0 5.1 5.2 Mometasone Furoate topical Monograph for Professionals. Drugs.com. American Society of Health-System Pharmacists. [11 March 2019]. (原始內容存檔於2020-08-05) (英語). 
  6. ^ 6.0 6.1 6.2 Mometasone Furoate eent Monograph for Professionals. Drugs.com. American Society of Health-System Pharmacists. [11 March 2019]. (原始內容存檔於2016-04-30). 
  7. ^ Mometasone. DrugBank. [30 April 2020]. (原始內容存檔於2019-06-29). 
  8. ^ Fischer J, Ganellin CR. Analogue-based Drug Discovery. John Wiley & Sons. 2006: 488. ISBN 9783527607495. 
  9. ^ World Health Organization. World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. 2021. WHO/MHP/HPS/EML/2021.02. 
  10. ^ British national formulary : BNF 76 76. Pharmaceutical Press. 2018: 265. ISBN 9780857113382. 
  11. ^ The Top 300 of 2020. ClinCalc. [11 April 2020]. (原始內容存檔於2020-03-18). 
  12. ^ Mometasone - Drug Usage Statistics. ClinCalc. [11 April 2020]. (原始內容存檔於2021-01-27).